COLORADO SPRINGS, Colo.,
March 18, 2015 /PRNewswire/ -- Cannabis Science, Inc.
(OTCQB: CBIS), a U.S. company specializing in cannabis
formulation-based drug development and
related consulting, today announced that Cohen Grassroots
Research, Inc. (CGR), Wall Street's leading independent micro-cap
and cannabis research firm, has been retained by the Company to
initiate intricate analytical coverage of the Company.
According to the 115-page initial Research Coverage Report,
Cannabis Science, Inc. (OTC QB: CBIS) is a pharmaceutical
and cannabis medical portfolio company researching and
commercializing cannabis-based medical applications for
multi-billion dollar markets. The Company is formulating treatments
for skin cancer (CS-S/BCC-1); for HIV (CS-S/BCC-l); and
neurological disorders (CS-NEURO-1), including drug-resistant
strains of Kaposi's Sarcoma, PTSD and other infectious diseases
using phytocannabinoid-based therapies. The Company is dedicated to
providing quality, innovative treatments to patients for a variety
of critical ailments.
In a few short months, the report states, new CEO and President
Raymond C. Dabney has restructured
and redirected the business model, adding revenue-producing
businesses and expanding the CBIS footprint worldwide. CBIS
has begun pre-investigational studies in pursuit of filing New Drug
applications with the U.S. Food and Drug Administration (FDA) for
CS-NEURO-1, CS-TATI -1, and CS-S/BCC-1. CBIS has raised funds
and is collaborating with partners to share synergies in R&D
and commercialization.
"Our estimates forecast revenues to grow from $0.1 million in FYE December 31, 2015 to approximately $64.52 million by FYE 2020. To meet our
forecasts, the Company will need to raise $14.0 million in equity capital in the next
couple of years to meet its capital requirements. Based on these
projections and assuming the Company raises the required capital,
the Cohen Target Price is $0.19,
268.9% higher than the current price," said D. Paul Cohen, President & CEO of Cohen
Grassroots Research, Inc.
To formulate its price target, Cohen Grassroots Research
performed an in-depth independent research analysis of CBIS,
including five-year financial and valuation projections. The report
is available at the Company website under the Investors information
tab or click here:
http://www.cannabisscience.com/downloads/cbis-analyst-report_cohengrassrootsresearch_03-14-2015.pdf
or
www.cohenresearch.com and www.cohengrassroots.com
CBIS is the cannabis industry's pure stock, analytical coverage
will be on a quarterly basis for the coming year. The decision to
provide this type of analytical coverage is based on the need to
articulate the progress of the Company, professionally, in a timely
manner, to the public. The Company's many cannabinoid drug
development initiatives underway internationally and the demand is
growing expotentially. Cannabinoids are classified as a
controlled substance under the Federal Controlled Substances Act of
1970.
Twenty-seven states plus the District
of Columbia have some form of medical cannabis regulations
in place. Growing support for legalization has led to a number of
companies entering the market. The report contends a large
market size and share will provide CBIS with significant growth
opportunities and the ability to treat patients in need. In
addition, the Company's experienced management team has built
strong partnerships in an estimated $2.7
billion medical cannabis market. Under Dabney's leadership,
multi-use compounds, solid R&D and continual innovation are
targeted at developing new compounds in an exciting and
medically-significant growth market, the report concludes.
About Cohen Grassroots Research, Inc.
Cohen Grassroots Research, Inc. is Wall Street's leading
independent micro-cap, small-cap and cannabis research firm.
The firm concentrates on emerging companies with strong management
teams focused on shareholder value and sustainable competitive
advantage. CGR, led by highly respected and well-known
security analyst, D. Paul Cohen,
highlights the Company's market opportunity, technology,
management, competition and other key differentiators that may
affect their long-term and short-term valuation. GRRD focuses
on those public companies that lack or have minimal Wall Street IR
research analyst coverage. CGR research reports are
commissioned and paid for by the companies covered, or by third
parties.
For more information, visit www.cohengrassroots.com.
The Cohen Grassroots Research disclaimer states: This
report/release is for informational purposes only. All
information contained herein is based on public information.
CGR complies with securities laws, regulations and ethical
standards as related to our legal and compliance
requirements. Do your own research.
Cohen Compensation Statement
Because we receive compensation for CGR's dissemination of the
Information, our publicly disseminated publications should not be
regarded in any manner whatsoever as independent. CGR is sometimes
paid for documents and distribution in cash, stock, Rule 144 stock,
warrants, options or other securities in lieu of or in addition to
CGR's stated compensation schedule. CGR services and documents
rendered are not related to, connected to, nor are they contingent
on a client's stock price performance. This compensation and
ownership of securities of a client's common stock constitutes a
conflict of interest as to our ability to remain objective in our
communication regarding our profiled companies. More information
can be received from our client company's website. The majority of
our assignments are for 30 days. We may write reports or promote a
given company on other occasions. The Company has paid 3,500,000
shares of Rule 144 common stock and $2,500 in compensation for this commercial
advertisement program. This document shall not be copied and is
copyrighted by Cohen Grassroots Research Inc. and D. Paul Cohen
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique
understanding of metabolic processes to provide novel treatment
approaches to a number of illnesses for which current treatments
and understanding remain unsatisfactory. Cannabinoids have an
extensive history dating back thousands of years, and currently,
there are a growing number of peer-reviewed scientific publications
that document the underlying biochemical pathways that cannabinoids
modulate. The Company works with leading experts in drug
development, medicinal characterization, and clinical research to
develop, produce, and commercialize novel therapeutic approaches
for the treatment for illnesses caused by infections as well as for
age-related illness. Our initial focus is on skin cancers,
HIV/AIDS, and neurological conditions. The Company is
proceeding with the research and development of its proprietary
drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1,
and CS-NEURO-1, respectively.
Forward-Looking Statements
This Press Release includes forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Act of 1934. A statement containing
words such as "anticipate," "seek," intend," "believe," "estimate,"
"expect," "project," "plan," or similar phrases may be deemed
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Some or all of the events
or results anticipated by these forward-looking statements may not
occur. Factors that could cause or contribute to such differences
include the future U.S. and global economies, the impact of
competition, and the Company's reliance on existing regulations
regarding the use and development of cannabis-based drugs. Cannabis
Science, Inc., does not undertake any duty nor does it intend to
update the results of these forward-looking statements. Safe Harbor
Statement. The Private Securities Litigation Reform Act of
1995 provides a 'safe harbor' for forward-looking statements.
Certain of the statements contained herein, which are not
historical facts are forward looking statements with respect to
events, the occurrence of which involved risks and
uncertainties. These forward-looking statements may be
impacted, either positively or negatively, by various
factors. Information concerning potential factors that could
affect the company are detailed from time to time in the company's
reports filed with the Securities and Exchange Commission.
Media Contacts:
Van Stone Publicity
Carrol Van Stone
carrol@vanstonepublicity.com
Tel: 304-671-0244
Cannabis Science, Inc.
Raymond C. Dabney
President & CEO, Co-Founder
info@cannabisscience.com
Tel: 1.888.889.0888
www.cannabisscience.com
Robert Kane
Director & CFO
info@cannabisscience.com
Tel: 1.888.889.0888
www.cohenresearch.com
www.cohengrassroots.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/cannabis-science-cbis-retains-cohen-grassroots-research-firm-to-initiate-coverage-beginning-with-a-115-page-analytical-report-300052286.html
SOURCE Cannabis Science, Inc.